Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda

Vaccine

Volumn 32, Issue 47, 2014, Pages 6303-6311

  LaMontagne, D Scott ^a   Mugisha, Emmanuel ^a   Pan, Yuanji ^c   Kumakech, Edward ^b   Ssemaganda, Aloysius ^d   Kemp, Troy J ^e   Cover, Jane ^a,b   Pinto, Ligia A ^e   Safaeian, Mahboobeh ^c  

^a PATH   (United States)

^b PATH   (Uganda)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Adolescents; HPV vaccine; Immunogenicity; Partially vaccinated; Uganda

Indexed keywords

VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; ARTICLE; BODY MASS; CHILD; CROSS-SECTIONAL STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MENARCHE; UGANDA; VACCINATION; ANTIBODY PRODUCTION; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UGANDA; UTERINE CERVICAL NEOPLASMS;

EID: 84907979711     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.071     Document Type: Article

References (48)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-28917.
2. Canfell K., Sitas F., Beral V. Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aust 2006, 185:482-486.
3. Habbema D., De Kok I.M., Brown M.L. Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q 2012, 90:5-37.
4. Brown R.E., Breugelmans J.G., Theodoratou D., Bénard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006, 22:663-670.
5. Giorgi Rossi P., Ricciardi A., Cohet C., Palazzo F., Furnari G., Valle S., et al. Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy. BMC Public Health 2009, 9. 10.1186/1471-2458-9-71.
6. Denny L.A., Sankaranarayanan R., De Vuyst H., Kim J.J., Adefuye P.O., Alemany L., et al. Recommendations for cervical cancer prevention in sub-saharan Africa. Vaccine 2013, 31(Suppl. 5):F73-F74.
7. Roteli-Martins C.M., Naud P., De Borba P., Teixeira J.C., De Carvalho N.S., Zahaf T., et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine up to 8.4 years of follow-up. Hum Vaccin Immunother 2012, 8:390-397.
8. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.
9. de Sanjose S., Quint W.G., Alemany L., Garaets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
10. Pedersen C., Petaja T., Strauss G., Runke H.C., Poder A., Richardus J.H., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007, 40:564-571.
11. Petäjä T., Pedersen C., Poder A., Strauss G., Catteau G., Thomas F., et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 2011, 129:2147-2157.
12. Rivera Medina D.M., Valencia A., de Velasquez A., Huang L.M., Prymula R., Garcia-Sicilla J., et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health 2010, 46:414-421.
13. Kim Y.J., Kim K.T., Kim J.H., Cha S.D., Kim J.W., Bae D.S., et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. J Korean Med Sci 2010, 25:1197-1204.
14. Romanowski B., Schwarz T., Ferguson L., Peters K., Dionne M., Schulze K., et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011, 7:1374-1386.
15. Schwarz T.F., Huang L.M., Medina D.M., Valencia A., Lin T.Y., Behre U., et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health 2012, 50:187-194.
16. Romanowski B., Schwarz T.F., Ferguson L.M., Ferguson M., Peters K., Dionne M., et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother 2014, 10(5). [Epub ahead of print].
17. Schmeink C.E., Bekkers R.L., Josefsson A., Richardus J.H., Berndtsson Blom K., David M.P., et al. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine 2011, 29:9276-9283.
18. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013, 309:1793-17802.
19. Safaeian M., Porras C., Schiffman M., Rodriguez A.C., Wacholder S., Gonzalez P., et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010, 102:1653-1662.
20. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle: efficacy of fewer than 3-doses of a bivalent HPV 16/18 vaccine against incident persistent HPV infection in Guanacaste, Costa Rica. J Natl Cancer Inst 2011, 103:1444-14451.
21. Safaeian M., Porras C., Pan Y., Kreimer A., Schiller J.T., Gonzalez P., et al. Durable antibody response following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in Costa Rica vaccine trial. Caner Prev Res 2013, 6:1242-1250.
22. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012, 20:F139-F148.
23. LaMontagne D.S., Barge S., Le N.T., Mugisha E., Penny M.E., Gandhi S., et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011, 89:821-830B.
24. Binagwaho A., Wagner C.M., Gatera M., Karema C., Nutt C.T., Ngabo F. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Organ 2012, 90:623-628.
25. Widgren K., Simonsen J., Valentiner-Branth P., Mølbak K. Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination programme in Denmark. Vaccine 2011, 29:9663-9667.
26. Brotherton J.M., Deeks S.L., Campbell-Lloyd S., Misrachi A., Passaris I., Peterson K., et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell Q Rep 2008, 32:457-461.
27. Penny M., Bartolini R., Mosqueira N.R., LaMontagne D.S., Mendoza M.A., Ramos I., et al. Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru. Vaccine 2011, 29:5022-5030.
28. Ladner J., Besson M.H., Hampshire R., Tapert L., Chirenje M., Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health 2012, 12:370.
29. Robbins S.C., Bernard D., McCaffery K., Skinner S.R. 'It's a logistical nightmare!' Recommendations for optimising human papillomavirus school-based vaccination experience. Sex Health 2010, 7:271-278.
30. Moodley I., Tathiah N., Mubaiwa V., Denny L. High uptake of Gardasil vaccine among 9-12-year-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-Natal, South Africa. S Afr Med J 2013, 103:318-321.
31. Levin C.E., Van Minh H., Odaga J., Rout S.S., Ngoc D.N., Menezes L., et al. Delivery cost of human papillomavirus vaccination of young adolescent girls in Peru, Uganda and Viet Nam. Bull World Health Organ 2013, 91:585-598.
32. Neuzil K.M., Canh D.G., Thiem V.D., Janmohamed A., Huong V.M., Tang Y., et al. Immunogenicity and reactogenicity of alternative schedules of human papillomavirus vaccine in adolescent girls in Vietnam: a cluster-randomized trial. JAMA 2011, 305:1424-1431.
33. LaMontagne D.S., Thiem V.D., Huong V.M., Tang Y., Neuzil K.M. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis 2013, 208:1325-1334.
34. Herrero R., Wacholder S., Rodríguez A.C., Solomon D., Gonzalez P., Kreimer A.R., et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011, 1:408-419.
35. Lin S.W., Ghosh A., Porras C., et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLOS ONE 2013, 8:e53067.
36. Sow P.S., Watson-Jones D., Kiviat N., Changalucha J., Mbaye K.D., Brown J., et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-15 year old HIV-seronegative African girls and young women. J Infect Dis 2013, 207:1753-1763.
37. Konno R., Tamura S., Dobbelaere K., Yoshikawa H. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years. Int J Gynecol Cancer 2010, 20:847-855.
38. Moscicki A.B. HPV infections in adolescents. Dis Markers 2007, 23:229-234.
39. Ferreccio C. Satellite symposium 12: recommendation for the introduction of the universal HPV vaccination in Chile 2012.
40. Santé et Services Sociaux Quebec. Human Papilloma Viruses (HPV). HPV Vaccination Program. Available at: [accessed 01.07.14]. http://www.msss.gouv.qc.ca/sujets/santepub/vaccination/index.php%3Faid=193.
41. South Africa.info SA targets cervical cancer with HPV vaccine campaign 2014, March, Available at: http://www.southafrica.info/services/health/hpv-vaccine-130314.htm#.U7MucvldWxU [accessed 01.07.14].
42. Herweijer E., Leval A., Ploner A., Eloranta S., Simard J.F., Dillnor J., et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014, 311(6):597-603.
43. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Assessment report: Cervarix, EMA/789820/2013 2013, November, Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000721/WC500160885.pdf [accessed 04.03.14].
44. World Health Organization. Summary of the SAGE April 2014 meeting. Available at: [accessed 01.07.14]. http://www.who.int/immunization/sage/meetings/2014/april/report_summary_april_2014/en/.
45. Lazcano-Ponce E. Comprehensive cervical cancer control programs in Mexico. Satellite symposium 12: HPV in Latin America & the Caribbean. 28th international papillomavirus conference 2012.
46. Garcia-Sicilia J., Schwarz T.F., Carmona A., Peters K., Malkin J.E., Tran P.M., et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health 2010, 46:142-151.
47. Wheeler C.M., Harvey B.M., Pichichero M.E., Simon M.W., Combs S.P., Blatter M.M., et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to health girls 11 to 18 years of age. Pediatr Infect Dis J 2011, 30:e225-e234.
48. Esposito S., Birlutiu V., Jarcuska P., Perino A., Man S.C., Vladareanu R., et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years. Pediatr Infect Dis J 2011, 30:e49-e55.